CloudMD $DOC.V - Months of selling and consolidation done?
CloudMD has been under selling pressure for months now. Today it closed its Vision Pros Acquisition and is expected to close its largest acquisition - Oncidium this month as well. The company can boast a 125-130mil revenue run rate. Vision Pros adds 22 mil in rev and 10% EBITDA margins to the bottom line for CloudMD.
I have a position in this company. It has not been an easy 3-4 months. The rest of the week will prove out if this was a one and done green day yesterday or if buyers are serious and ready to take control again. PT on DOC is $3.96. Was a "top pick" on Bloomberg MarketCall June 23rd. At some point the market is going to start respecting that revenue and positive EBITDA that the company is set to report for this full fiscal year. currently trading at 3x sales.
This should definitely be on the watchlist now. Look to see Buyers control Price around the 2SD Cross as highlighted. DCA approach the play here. DOC.V is a long hold for myself. Hope the chart and thoughts help.
Please do you own DD and follow your own trading rules.
Cheers,
Luke
I have a position in this company. It has not been an easy 3-4 months. The rest of the week will prove out if this was a one and done green day yesterday or if buyers are serious and ready to take control again. PT on DOC is $3.96. Was a "top pick" on Bloomberg MarketCall June 23rd. At some point the market is going to start respecting that revenue and positive EBITDA that the company is set to report for this full fiscal year. currently trading at 3x sales.
This should definitely be on the watchlist now. Look to see Buyers control Price around the 2SD Cross as highlighted. DCA approach the play here. DOC.V is a long hold for myself. Hope the chart and thoughts help.
Please do you own DD and follow your own trading rules.
Cheers,
Luke
כתב ויתור
המידע והפרסומים אינם אמורים להיות, ואינם מהווים, עצות פיננסיות, השקעות, מסחר או סוגים אחרים של עצות או המלצות שסופקו או מאושרים על ידי TradingView. קרא עוד בתנאים וההגבלות.